TITLE:
ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer

CONDITION:
Metastases

INTERVENTION:
ALIMTA

SUMMARY:

      This is a non-randomized, phase 1, study with the primary objective of determining the
      toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10
      minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in
      lightly or heavily pre-treated patients with locally advanced or metastatic cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of metastatic or locally advanced cancer

          -  Prior chemotherapy is allowed

          -  Adequate bone marrow, liver and kidney function

        Exclusion Criteria:

          -  Prior treatment with ALIMTA

          -  Brain metastasis

          -  Pregnancy or breast feeding
      
